A phase I dose-escalating study to investigate the safety, tolerability, pharmacokinetics and dosimetry of a single dose of Y-humanized PAM4 IgG in patients with locally advanced/metastatic pancreatic cancer

Trial Profile

A phase I dose-escalating study to investigate the safety, tolerability, pharmacokinetics and dosimetry of a single dose of Y-humanized PAM4 IgG in patients with locally advanced/metastatic pancreatic cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 02 May 2011

At a glance

  • Drugs Y-90 clivatuzumab tetraxetan (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Immunomedics
  • Most Recent Events

    • 02 May 2011 Results have been published in Clinical Cancer Research according to an Immunomedics media release; results wre also reported in the media release.
    • 28 Jan 2010 Results presented in an Immunomedics media release.
    • 22 Jan 2008 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top